Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...

KIO-104 is for the treatment of a wide range of ocular diseases, including ocular inflammation, uveitis, age-related macular ...

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting ...

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).